Bod Science Limited

As of June 30, 2024, Bod Science Limited has 177.34M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 4.83, and the price-to-book ratio stands at -0.80.

As of June 30, 2024, Bod Science Limited maintains a current ratio of 0.30, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -220.73, reflecting losses generated across the asset base. Inventory turnover of 1.27 indicates how many times Bod Science Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on December 19, 2023, Bod Science Limited's stock has declined approximately 84.00% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.06.

Over the twelve months ended June 30, 2024, Bod Science Limited posted a gross margin of 29.53, reflecting its pricing power and cost economics. The operating margin of -674.21 and net profit margin of -741.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield stands at 46.83, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -17.97, meaning Bod Science Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Bod Science Limited's most recent stock split took place on September 5, 2022 with a 1000:1013 split ratio.

As of June 30, 2024, Bod Science Limited has an Altman Z-Score of -35.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.